Immuneering Corporation announced on August 21, 2025, that it entered into a definitive securities purchase agreement for a private placement, expected to generate approximately $25 million in upfront gross proceeds. This financing aims to support the company's ongoing efforts to advance atebimetinib, its Deep Cyclic Inhibitor of MEK.
Under the agreement, Immuneering will sell 6,329,113 unregistered shares of Class A common stock at a purchase price of $3.95 per share, or pre-funded warrants for certain investors. Additionally, accompanying purchase warrants to acquire 2,848,096 shares of Class A common stock at an exercise price of $5.50 per share will be issued.
The $3.95 per share purchase price for the Class A common stock represents a premium of approximately 15% compared to the company’s last reported closing price on August 20, 2025. The closing of the private placement is subject to customary conditions and is expected to occur on or about August 26, 2025. This capital infusion is critical for extending the company's financial runway and accelerating the development of its lead asset.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.